Literature DB >> 25870172

Molecular differences in transition zone and peripheral zone prostate tumors.

Jennifer A Sinnott1, Jennifer R Rider2, Jessica Carlsson3, Travis Gerke4, Svitlana Tyekucheva5, Kathryn L Penney6, Howard D Sesso7, Massimo Loda8, Katja Fall9, Meir J Stampfer6, Lorelei A Mucci10, Yudi Pawitan11, Sven-Olof Andersson3, Ove Andrén3.   

Abstract

Prostate tumors arise primarily in the peripheral zone (PZ) of the prostate, but 20-30% arise in the transition zone (TZ). Zone of origin may have prognostic value or reflect distinct molecular subtypes; however, it can be difficult to determine in practice. Using whole-genome gene expression, we built a signature of zone using normal tissue from five individuals and found that it successfully classified nine tumors of known zone. Hypothesizing that this signature captures tumor zone of origin, we assessed its relationship with clinical factors among 369 tumors of unknown zone from radical prostatectomies (RPs) and found that tumors that molecularly resembled TZ tumors showed lower mortality (P = 0.09) that was explained by lower Gleason scores (P = 0.009). We further applied the signature to an earlier study of 88 RP and 333 transurethral resection of the prostate (TURP) tumor samples, also of unknown zone, with gene expression on ~6000 genes. We had observed previously substantial expression differences between RP and TURP specimens, and hypothesized that this might be because RPs capture primarily PZ tumors, whereas TURPs capture more TZ tumors. Our signature distinguished these two groups, with an area under the receiver operating characteristic curve of 87% (P < 0.0001). Our findings that zonal differences in normal tissue persist in tumor tissue and that these differences are associated with Gleason score and sample type suggest that subtypes potentially resulting from different etiologic pathways might arise in these zones. Zone of origin may be important to consider in prostate tumor biomarker research.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25870172      PMCID: PMC4572920          DOI: 10.1093/carcin/bgv051

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  20 in total

1.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

Authors:  Andrea Sboner; Francesca Demichelis; Stefano Calza; Yudi Pawitan; Sunita R Setlur; Yujin Hoshida; Sven Perner; Hans-Olov Adami; Katja Fall; Lorelei A Mucci; Philip W Kantoff; Meir Stampfer; Swen-Olof Andersson; Eberhard Varenhorst; Jan-Erik Johansson; Mark B Gerstein; Todd R Golub; Mark A Rubin; Ove Andrén
Journal:  BMC Med Genomics       Date:  2010-03-16       Impact factor: 3.063

2.  Gene expression profiling of the human prostate zones.

Authors:  Leonie van der Heul-Nieuwenhuijsen; Peter J M Hendriksen; Theo H van der Kwast; Guido Jenster
Journal:  BJU Int       Date:  2006-10       Impact factor: 5.588

3.  The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.

Authors:  Andreas Pettersson; Rebecca E Graff; Scott R Bauer; Michael J Pitt; Rosina T Lis; Edward C Stack; Neil E Martin; Lauren Kunz; Kathryn L Penney; Azra H Ligon; Catherine Suppan; Richard Flavin; Howard D Sesso; Jennifer R Rider; Christopher Sweeney; Meir J Stampfer; Michelangelo Fiorentino; Philip W Kantoff; Martin G Sanda; Edward L Giovannucci; Eric L Ding; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-26       Impact factor: 4.254

4.  Expression of bone morphogenetic proteins in human metastatic prostate and breast cancer.

Authors:  Dragica Bobinac; Ivana Marić; Sanja Zoricić; Josip Spanjol; Gordana Dordević; Elvira Mustać; Zeljko Fuckar
Journal:  Croat Med J       Date:  2005-06       Impact factor: 1.351

5.  mRNA expression signature of Gleason grade predicts lethal prostate cancer.

Authors:  Kathryn L Penney; Jennifer A Sinnott; Katja Fall; Yudi Pawitan; Yujin Hoshida; Peter Kraft; Jennifer R Stark; Michelangelo Fiorentino; Sven Perner; Stephen Finn; Stefano Calza; Richard Flavin; Matthew L Freedman; Sunita Setlur; Howard D Sesso; Swen-Olof Andersson; Neil Martin; Philip W Kantoff; Jan-Erik Johansson; Hans-Olov Adami; Mark A Rubin; Massimo Loda; Todd R Golub; Ove Andrén; Meir J Stampfer; Lorelei A Mucci
Journal:  J Clin Oncol       Date:  2011-05-02       Impact factor: 44.544

6.  ERG rearrangement is present in a subset of transition zone prostatic tumors.

Authors:  Sara M Falzarano; Maria Navas; Kelly Simmerman; Eric A Klein; Mark A Rubin; Ming Zhou; Cristina Magi-Galluzzi
Journal:  Mod Pathol       Date:  2010-08-06       Impact factor: 7.842

7.  Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion.

Authors:  Charles C Guo; Geyan Zuo; Dongdong Cao; Patricia Troncoso; Bogdan A Czerniak
Journal:  Mod Pathol       Date:  2009-04-24       Impact factor: 7.842

8.  A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate.

Authors:  D R Greene; T M Wheeler; S Egawa; J K Dunn; P T Scardino
Journal:  J Urol       Date:  1991-10       Impact factor: 7.450

9.  Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer.

Authors:  Julie L Kasperzyk; Stephen P Finn; Richard Flavin; Michelangelo Fiorentino; Rosina Lis; Whitney K Hendrickson; Steven K Clinton; Howard D Sesso; Edward L Giovannucci; Meir J Stampfer; Massimo Loda; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-10-15       Impact factor: 4.254

10.  Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer.

Authors:  Sunita R Setlur; Kirsten D Mertz; Yujin Hoshida; Francesca Demichelis; Mathieu Lupien; Sven Perner; Andrea Sboner; Yudi Pawitan; Ove Andrén; Laura A Johnson; Jeff Tang; Hans-Olov Adami; Stefano Calza; Arul M Chinnaiyan; Daniel Rhodes; Scott Tomlins; Katja Fall; Lorelei A Mucci; Philip W Kantoff; Meir J Stampfer; Swen-Olof Andersson; Eberhard Varenhorst; Jan-Erik Johansson; Myles Brown; Todd R Golub; Mark A Rubin
Journal:  J Natl Cancer Inst       Date:  2008-05-27       Impact factor: 13.506

View more
  13 in total

1.  Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.

Authors:  Mrishta Brizmohun Appayya; Harbir S Sidhu; Nikolaos Dikaios; Edward W Johnston; Lucy Am Simmons; Alex Freeman; Alexander Ps Kirkham; Hashim U Ahmed; Shonit Punwani
Journal:  Br J Radiol       Date:  2017-12-15       Impact factor: 3.039

2.  LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality.

Authors:  Valentina Fiano; Daniela Zugna; Chiara Grasso; Morena Trevisan; Luisa Delsedime; Luca Molinaro; Anna Gillio-Tos; Franco Merletti; Lorenzo Richiardi
Journal:  Epigenetics       Date:  2016-11-28       Impact factor: 4.528

3.  Cholesterol uptake and regulation in high-grade and lethal prostate cancers.

Authors:  Konrad H Stopsack; Travis A Gerke; Ove Andrén; Swen-Olof Andersson; Edward L Giovannucci; Lorelei A Mucci; Jennifer R Rider
Journal:  Carcinogenesis       Date:  2017-08-01       Impact factor: 4.944

Review 4.  Prostate zones and cancer: lost in transition?

Authors:  Amin Ali; Alexander Du Feu; Pedro Oliveira; Ananya Choudhury; Robert G Bristow; Esther Baena
Journal:  Nat Rev Urol       Date:  2021-10-19       Impact factor: 14.432

5.  Prognostic Utility of a New mRNA Expression Signature of Gleason Score.

Authors:  Jennifer A Sinnott; Sam F Peisch; Svitlana Tyekucheva; Travis Gerke; Rosina Lis; Jennifer R Rider; Michelangelo Fiorentino; Meir J Stampfer; Lorelei A Mucci; Massimo Loda; Kathryn L Penney
Journal:  Clin Cancer Res       Date:  2016-09-23       Impact factor: 12.531

6.  A short-term intervention with selenium affects expression of genes implicated in the epithelial-to-mesenchymal transition in the prostate.

Authors:  Dieuwertje E G Kok; Lambertus A L M Kiemeney; Gerald W Verhaegh; Jack A Schalken; Emile N J T van Lin; J P Michiel Sedelaar; J Alfred Witjes; Christina A Hulsbergen-van de Kaa; Pieter van 't Veer; Ellen Kampman; Lydia A Afman
Journal:  Oncotarget       Date:  2017-02-07

7.  TMPRSS2-ERG fusion impacts anterior tumor location in men with prostate cancer.

Authors:  Kosj Yamoah; Priti Lal; Shivanshu Awasthi; Arash O Naghavi; Robert J Rounbehler; Travis Gerke; Anders E Berglund; Julio M Pow-Sang; Edward M Schaeffer; Jasreman Dhillon; Jong Y Park; Timothy R Rebbeck
Journal:  Prostate       Date:  2020-11-03       Impact factor: 4.104

8.  Increased transcriptional and metabolic capacity for lipid metabolism in the peripheral zone of the prostate may underpin its increased susceptibility to cancer.

Authors:  Omar Al Kadhi; Maria H Traka; Antonietta Melchini; Perla Troncoso-Rey; Wiktor Jurkowski; Marianne Defernez; Purnima Pachori; Robert D Mills; Richard Y Ball; Richard F Mithen
Journal:  Oncotarget       Date:  2017-05-17

9.  Accuracy of dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate cancer: systematic review and meta-analysis.

Authors:  Zhiqiang Chen; Yi Zheng; Guanghai Ji; Xinxin Liu; Peng Li; Lei Cai; Yulin Guo; Jian Yang
Journal:  Oncotarget       Date:  2017-08-17

10.  SFRP4 gene expression is increased in aggressive prostate cancer.

Authors:  Elise Sandsmark; Maria K Andersen; Anna M Bofin; Helena Bertilsson; Finn Drabløs; Tone F Bathen; Morten B Rye; May-Britt Tessem
Journal:  Sci Rep       Date:  2017-10-27       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.